1 June 2016 - The TGA has approved a new use for Roche's Perjeta (pertuzumab).

Perjeta is now approved for use in combination with trastuzumab and chemotherapy for the neo-adjuvant treatment of patients with inflammatory or locally advanced HER2-positive breast cancer as part of a complete treatment regimen.

The FDA approved the use of Perjeta for this indication on 30 September 2013.

For more details, go to: http://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines